ANN ARBOR, Mich.--(BUSINESS WIRE)--Leaders from the Michigan bio-industry, academia, and policy realms are joining to discuss how to best unleash Michigan’s biosciences R&D and manufacturing potential and drive future business growth at MichBio’s inaugural Michigan Bio-Industry Growth Summit at the Radisson Lansing at the Capitol on Wednesday, February 3rd, 2016.
MichBio, the association for Michigan’s biosciences industry, will release and discuss the Michigan Bio-Industry Strategic Roadmap. The Roadmap is the culmination of a year-long strategic planning initiative focusing on how to grow Michigan’s biosciences industry into a market leader. Over two hundred stakeholders participated in the grass-roots data gathering effort. The initiative is being conducted in partnership with the Business Leaders for Michigan (BLM) and the University Research Corridor (URC).
“Michigan’s bio-industry is at a critical point given the rapidly changing dynamics in the healthcare delivery marketplace, regulatory landscape, and global economy,” remarked Stephen Rapundalo, MichBio President and CEO. “For the state’s bioscience research, development, and manufacturing enterprise to have future success, a shared and executable vision with performance measures is required.”
The Michigan Bio-Industry Growth Summit will feature the following panelists, speakers and others:
| Hon. Brian Calley, Lt. Governor, State of Michigan |
| Hon. Tonya Schuitmaker, State Senator |
| Hon. Rebekah Warren, State Senator |
| Hon. Sam Singh, State Representative |
| Hon. Jim Tedder, State Representative |
| Mark Leahey, CEO, Medical Device Manufacturers Association (MDMA) |
| Liz Powell, Esq., MPH, G2G Consulting |
| Doug Rothwell, President and CEO, Business Leaders for Michigan |
| Michael Jandernoa, Director, Perrigo |
| Jeff Mason, Executive Director, University Research Corridor |
| Kevin Lobo, President and CEO, Stryker Corporation |
| Roger Newton, PhD, Esperion Therapeutics |
| Mina Sooch, CEO, Gemphire Therapeutics |
The Michigan Bio-Industry Roadmap is intended to be an operational ‘game plan’ to enable growth over the next three to five years. The plan identifies key opportunities with defined actions and metrics. The Roadmap and bio-industry stakeholders focus on functional areas such as: Innovation, industry growth, business climate, capital access and education/talent development. In addition, the Roadmap assessed needs, challenges and opportunities across several bio-industry sectors and market areas where Michigan has a recognized strength and/or potential for growth.
Admission for this special event is $99 for MichBio Members and $149US for non-members. Attendees can register at michbio.org or by calling 734-527-9150.
